Isis Pharmaceuticals, Inc. (NASDAQ:ISIS): Closing price $36.27
On Thursday, Isis said that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMN in children suffering from spinal muscular atrophy, show that the majority of SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests as long as 14 months following a single injection of the drug. The Phase 1 data, including these preliminary follow-on data, will be presented at the International Congress of the World Muscle Society by Dr. Kathy Swoboda on October 3. Spinal muscular atrophy is a severe and rare genetic neuromuscular disease described by muscle atrophy and weakness and is the most common genetic cause of infant mortality.
Eli Lilly and Co. (NYSE:LLY): Closing price $53.86
Exosome Diagnostics announced Thursday that it will work jointly with Eli Lilly for biomarker discovery and validation, employing Exosome Diagnostics proprietary EXO50 nucleic acid extraction kit. Through the terms, Lilly will gain early access to Exosome Diagnostics tech in order to help identify key gene mutations and expression levels in blood that may be linked with drug response and disease recurrence. Financials of the transaction were not reported.
Illumina, Inc. (NASDAQ:ILMN): Closing price $81.67
Illumina said Thursday that its company Verinata Health has published additional peer-reviewed data indicating that Verinata’s non-invasive verifi prenatal test correctly detects aneuploidies across all test samples, including patients having very low fetal fractions (cell-free DNA fragments in maternal blood contributed from the fetus). The publication also documented that fetal fractions are distinct for pregnancies in which the fetus has Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and other aneuploidies analyzed by the verifi prenatal test.
Medifast, Inc. (NYSE:MED): Closing price $26.08
Medifast has reached a settlement with the Securities and Exchange Commission in regards to the restatement of certain items in the former’s previously-issued financial statements for the years 2006 through 2009. Under the terms, Medifast, without admitting or denying the Commission’s findings, agreed to the entry of a cease-and-desist order, and will pay a civil penalty of $200,000.
By electing to accept the deal, the SEC considered remedial acts undertaken by the firm, including retention of additional executive management and accounting personnel, and the improvement of internal controls. Medifast is a domestic maker and provider of clinically proven, portion-controlled weight-loss products and programs.